ID

27344

Descrizione

Study ID: 103534 Clinical Study ID: 103534 Study Title: Evaluate the immunogenicity, reactogenicity, safety of 4 different formulations of GSK Biologicals' conjugate vaccine (MenACWY) vs 1 dose of MenC-CRM197 or Mencevax™ ACWY in children aged 12-14 months & 3-5 years Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00196976 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed clinical study under GSK sponsorship. The product that is studied in this clinical study, together with the rights to the data and results generated, has been transferred by GSK to Pfizer. GSK’s Clinical Study Register is no longer maintained for this study. To request access to clinical study data from Pfizer, go here: http://www.pfizer.com/research/clinical_trials/trial_data_and_results Generic Name: Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine Trade Name: Nimenrix Study Indication: Infections, Meningococcal Booster Vaccination Only for subjects who are part of the group with the selected MenACWY-TT formulation and the control group.) “Subjects enrolled at 3 – 5 years of age”

collegamento

http://www.pfizer.com/research/clinical_trials/trial_data_and_results

Keywords

versioni (1)
  1. 08/11/17 08/11/17 -
Titolare del copyright

Pfizer

Caricato su

8 novembre 2017

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 3.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Meningococcal Infections Vaccination in children NCT00196976

Inglese

Workbook 2 Study Conclusion Stage 2

1 moduli  
Administrative Documentation
Descrizione

Administrative Documentation

Alias
UMLS CUI-1
C1320722
Subject Number
Descrizione

Subject Number

Tipo di dati

integer

Alias
UMLS CUI [1]
C2348585
Follow-up studies Stage 2
Descrizione

Follow-up studies Stage 2

Alias
UMLS CUI-1
C0016441
Would the subject be willing to participate in a follow-up study?
Descrizione

Follow-up study participation

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0016441
UMLS CUI [1,2]
C2348568
No, please specify the most appropriate reason
Descrizione

Follow-up study participation

Tipo di dati

text

Alias
UMLS CUI [1,1]
C3274571
UMLS CUI [1,2]
C2348568
STUDY CONCLUSION STAGE 2
Descrizione

STUDY CONCLUSION STAGE 2

Alias
UMLS CUI-1
C1707478
UMLS CUI-2
C0008976
UMLS CUI-3
C0042210
Did any elimination criteria become applicable during the study ?
Descrizione

Elimination criteria

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0680251
Did any elimination criteria become applicable during the study? Please specify
Descrizione

Elimination criteria

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1521902
Administrative Documentation
Descrizione

Administrative Documentation

Alias
UMLS CUI-1
C1320722
I confirm that I have reviewed the data in this Case Report Form for this subject. All information entered by myself or my colleagues is, to the best of my knowledge, complete and accurate, as of the date below. Investigator's signature:
Descrizione

Investigators signature

Tipo di dati

text

Alias
UMLS CUI [1]
C2346576
Date
Descrizione

Signature Date

Tipo di dati

date

Alias
UMLS CUI [1]
C0807937
Printed Investigator's name:
Descrizione

Printed Investigator's name:

Tipo di dati

text

Alias
UMLS CUI [1]
C2826892
Ritorna all'inizio della pagina

Similar models

Workbook 2 Study Conclusion Stage 2

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Administrative Documentation
C1320722 (UMLS CUI-1)
Subject Number
Item
Subject Number
integer
C2348585 (UMLS CUI [1])
Item Group
Follow-up studies Stage 2
C0016441 (UMLS CUI-1)
Follow-up study participation
Item
Would the subject be willing to participate in a follow-up study?
boolean
C0016441 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
Item
No, please specify the most appropriate reason
text
C3274571 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
Follow-up study participation
Code List
No, please specify the most appropriate reason
CL Item
Adverse Events, or Serious Adverse Events, please specify: (Adverse Events, or Serious Adverse Events, please specify:)
CL Item
Other, please specify: (Other, please specify:)
Item Group
STUDY CONCLUSION STAGE 2
C1707478 (UMLS CUI-1)
C0008976 (UMLS CUI-2)
C0042210 (UMLS CUI-3)
Elimination criteria
Item
Did any elimination criteria become applicable during the study ?
boolean
C0680251 (UMLS CUI [1])
Elimination criteria
Item
Did any elimination criteria become applicable during the study? Please specify
text
C0680251 (UMLS CUI [1,1])
C1521902 (UMLS CUI [1,2])
Item Group
Administrative Documentation
C1320722 (UMLS CUI-1)
Investigators signature
Item
I confirm that I have reviewed the data in this Case Report Form for this subject. All information entered by myself or my colleagues is, to the best of my knowledge, complete and accurate, as of the date below. Investigator's signature:
text
C2346576 (UMLS CUI [1])
Signature Date
Item
Date
date
C0807937 (UMLS CUI [1])
Printed Investigator's name:
Item
Printed Investigator's name:
text
C2826892 (UMLS CUI [1])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial